Midwest CEPAC Meeting: Ovarian Cancer
The Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. The Midwest CEPAC convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Midwest CEPAC directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. On September 14, 2017, the Council will review the ICER Evidence Report on Ovarian Cancer. Ovarian cancer is the most common cause of gynecologic cancer death and fifth-leading cause of cancer death in women. There are nearly 200,000 women currently living with ovarian cancer; each year over 22,000 new cases are diagnosed and there are approximately 14,000 deaths attributable to the disease. ICER's report focuses on ovarian cancers with high-grade serous or mixed serous/endometrioid histology, which represent the population most likely to respond to current treatment options and are common entry criteria for clinical trials. At the September 14 meeting, we will discuss evidence on the comparative clinical effectiveness and value of poly (ADP-ribose) polymerase (PARP) inhibitors: rucaparib, niraparib, olaparib. The meeting will be held in the Century BC Room of the University of Missouri-St. Louis Millennium Student Center. For more information, and to view reports and meeting materials as they become available, please visit the ICER website.